- Home
- CLDI vs MDAI Comparison
CLDI vs MDAI Comparison
Compare CLDI & MDAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLDI
- MDAI
- Stock Information
- Founded
- CLDI 2014
- MDAI 2013
- Country
- CLDI United States
- MDAI United States
- Employees
- CLDI N/A
- MDAI N/A
- Industry
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- MDAI Medical/Dental Instruments
- Sector
- CLDI Health Care
- MDAI Health Care
- Exchange
- CLDI Nasdaq
- MDAI Nasdaq
- Market Cap
- CLDI 35.2M
- MDAI 28.3M
- IPO Year
- CLDI N/A
- MDAI N/A
- Fundamental
- Price
- CLDI $1.05
- MDAI $1.95
- Analyst Decision
- CLDI Strong Buy
- MDAI Strong Buy
- Analyst Count
- CLDI 3
- MDAI 2
- Target Price
- CLDI $16.67
- MDAI $4.75
- AVG Volume (30 Days)
- CLDI 2.7M
- MDAI 616.5K
- Earning Date
- CLDI 03-14-2025
- MDAI 03-26-2025
- Dividend Yield
- CLDI N/A
- MDAI N/A
- EPS Growth
- CLDI N/A
- MDAI N/A
- EPS
- CLDI N/A
- MDAI N/A
- Revenue
- CLDI N/A
- MDAI $27,264,000.00
- Revenue This Year
- CLDI N/A
- MDAI $61.78
- Revenue Next Year
- CLDI N/A
- MDAI N/A
- P/E Ratio
- CLDI N/A
- MDAI N/A
- Revenue Growth
- CLDI N/A
- MDAI 44.52
- 52 Week Low
- CLDI $0.58
- MDAI $0.82
- 52 Week High
- CLDI $16.80
- MDAI $3.25
- Technical
- Relative Strength Index (RSI)
- CLDI 45.04
- MDAI 45.75
- Support Level
- CLDI $1.16
- MDAI $1.86
- Resistance Level
- CLDI $1.30
- MDAI $2.25
- Average True Range (ATR)
- CLDI 0.24
- MDAI 0.15
- MACD
- CLDI 0.01
- MDAI -0.00
- Stochastic Oscillator
- CLDI 40.10
- MDAI 37.50
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical stage immuno-oncology company pioneering the development and commercialization of novel, potent and efficient stem cell-based platforms for delivery and potentiation of oncolytic viruses for the treatment of cancer.
About MDAI Spectral AI Inc.
Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.